RASAL2 and breast carcinoma: Using an independent patient cohort of TNBC/BRCA-mutant breast cancer patients [20], we found that transcripts of RASAL2 variant 2, but not variant 1, was significantly upregulated following treatment (Figs. 1D and S1C, D).